Gupta Pramod 4

What Happened

• Pramod Gupta, EVP, Pharmaceuticals and BD at Unicycive Therapeutics (UNCY), received a grant of 169,500 restricted stock units (RSUs) on 2026-05-14. The Form 4 lists the acquisition as a derivative award (transaction code A) with a reported price of $0.00 (the award itself has no immediate cash purchase price).
• These RSUs are payable solely in common stock and will vest one-third on each anniversary of the grant date for three years, subject to continued service. Because this is an equity compensation award (not an open-market purchase or sale), it is a compensation grant rather than a direct bullish market purchase.

Key Details

• Transaction date: 2026-05-14; Filing date: 2026-05-20 (filed 4 business days after the transaction, which exceeds the 2-business-day Form 4 deadline).
• Award: 169,500 RSUs; reported acquisition price: $0.00 (derivative award).
• Vesting: 1/3 each year on the grant anniversary for 3 years (see footnote F1).
• Shares owned after transaction: not disclosed in the Form 4.
• Footnote: F1 confirms the grant is an RSU award payable in common stock and subject to time-based vesting.
• Timeliness: The Form 4 appears to have been filed late relative to the standard 2-business-day reporting requirement.

Context

• RSU grants are a form of compensation; they do not represent immediate purchases or sales of shares until they vest and are delivered. They typically reflect retention and compensation rather than an immediate insider market signal.
• Because the award vests over time and the Form 4 shows no immediate sale or exercise, there is no immediate impact on marketable shares held by the insider until vesting occurs.